



Republic of the Philippines  
Department of Health  
**FOOD AND DRUG ADMINISTRATION**



**FDA ADVISORY**  
No. 2021-1695-A

'06 AUG 2021

**TO: THE GENERAL PUBLIC**

**SUBJECT: Lifting the Advisory on the Notified Cosmetic Product "LUXE ORGANIX AHA-BHA NIACINAMIDE MIRACLE SOLUTIONS SOAP FOR FACE & BODY" under FDA Advisory No. 2021-1695 "Public Health Warning Against the Purchase and Use of Non-Compliant Luxe Organix AHA-BHA Niacinamide Miracle Solutions Soap for Face & Body" Dated 07 July 2021**

The Food and Drug Administration (FDA) informs the public that the Cosmetic **Luxe Organix AHA-BHA Niacinamide Miracle Solutions Soap for Face & Body** with **Notification No. 1000007153539**, has been notified by the Market Authorization Holder, Genson Distribution Inc., in accordance with existing FDA rules and regulations.


Accordingly, the warning against the purchase and use of the subject product as mentioned in FDA Advisory No. 2021-1695 and FDA Order No. 2021-1414 is hereby lifted.

The public is advised to always check if a Cosmetic product is notified with the FDA by using the FDA Verification Portal feature accessible at <https://verification.fda.gov.ph> which may be used by typing in the name of the product before purchasing. For more information or inquiries, please email us at [cchuhsrr\\_prsdd@fda.gov.ph](mailto:cchuhsrr_prsdd@fda.gov.ph). You may also call the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research at telephone number **(02) 8857-1900 loc. 8113 or 8117**.

To report the sale or distribution of any unnotified/unregistered health product, kindly email FDA via [ereport@fda.gov.ph](mailto:ereport@fda.gov.ph).

Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.

  
**ROLANDO ENRIQUE D. DOMINGO, MD**  
Director General

DTN 20210706085340

